Table 1 Study population baseline clinicodemographic characteristics stratified by coronary artery disease or heart failure diagnoses

n = 512

n = 10, 369

Sociodemographic data

Age (IQR)

64 (18.5)

51 (29)

< 0.001

Sex

< 0.001

Male

331 (64.65%)

5449 (52.56%)

Female

181 (35.35%)

4918 (47.44%)

Nationality

0.023

Filipino

512 (100.00%)

10,277 (99.11%)

Others

0

92 (0.89%)

Body mass index^a

24.61 (5.26)

24.98 (6.08)

0.145

Comorbid diseases and risks

Non-neurologic

Smoking history

108 (21.09%)

918 (8.85%)

< 0.001

Hypertension

411 (80.27%)

3236 (31.21%)

< 0.001

Diabetes

261 (50.98%)

1930 (18.61%)

< 0.001

Chronic obstructive pulmonary disease

29 (5.66%)

127 (1.22%)

< 0.001

Bronchial asthma

20 (3.91%)

443 (4.27%)

0.689

Dyslipidemia

Kidney disease

110 (21.48%)

501 (4.83%)

< 0.001

Obesity^a

36 (14.81%)

729 (17.05%)

0.366

Healthcare worker

17 (3.32%)

859 (8.28%)

< 0.001

Neurologic history/ Chronic neurologic disease

Stroke

57 (11.13%)

264 (2.55%)

< 0.001

Epilepsy

0

27 (0.26%)

0.637

Others

10 (1.95%)

62 (0.60%)

< 0.001

COVID severity

< 0.001

Severe/Critical

318 (62.48%)

3743 (36.55%)

Mild/Moderate

191 (37.52%)

6499 (63.45%)

Treatments received

Tocilizumab

83 (16.21%)

946 (9.12%)

< 0.001

Steroids

242 (47.27%)

2602 (25.09%)

< 0.001

Remdesivir

128 (25.00%)

1216 (11.73%)

< 0.001

Anticoagulation

54 (10.55%)

977 (9.42%)

0.396

Antiplatelets

15 (2.93%)

48 (0.46%)

< 0.001

Convalescent plasma therapy

24 (4.69%)

239 (2.30%)

0.001

Hemoperfusion

10 (1.95%)

115 (1.11%)

0.080